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ABSTRACT
Transfusion has been associated with increased morbidity and short- and long­
term mortality after cardiac surgery. However, the physiological effects of transfusion in 
this setting are poorly described. This study aimed to examine the effects of transfusion 
on blood composition and characteristics after cardiac surgery.
1,134 patients underwent an isolated coronary artery bypass graft surgery with 
no post-operative complications. Of these, 407 (35.8%) patients received a transfusion. 
Propensity-matching was used to generate a balanced cohort of 636 patients. 26 
variables from standard blood tests were retrospectively collected. A repeated measures 
analysis of variance test was used to examine how these variables changed over time and 
if the changes were affected by transfusion.
11 of the 26 variables were shown to be significantly affected by transfusion. 
Transfusion caused a relative increase in blood urea nitrogen, creatinine, red blood cells, 
hematocrit, mean corpuscular hemoglobin concentration, and platelets. Conversely, it 
was associated with a decrease in calcium, carbon dioxide, pH, pC>2, white blood cell 
count, and mean corpuscular hemoglobin.
When examining associated clinical relevance of the significant (and non­
significant) results, several trends begin to emerge. There was little evidence that 
transfusion cured anemia, at least by the traditional measure of hemoglobin, although the 
data suggests that it does increase the oxygen-carrying capacity of the blood. However, 
hepatic and renal function may be impaired by the administration of donor blood 
products.
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CHAPTER 1
INTRODUCTION AND REVIEW OF THE LITERATURE
One-fifth of all blood transfusions in the United States go to patients undergoing 
cardiac surgery (Stover, Siegel et al. 1998; Shander, Moskowitz et al. 2005). 13% of 
these transfusions go to patients who received a combination of coronary artery bypass 
grafting (CABG) and valvular surgery (Stover, Siegel et al. 1998; Shander, Moskowitz 
et al. 2005). Additionally, patients are more likely to be transfused if the procedure 
utilizes cardio-pulmonary bypass (on-pump) compared to an off-pump operation 
(Surgenor, Kramer et al. 2009).
Recent studies further confirmed the negative effects associated with the 
administration of blood products in both the short- and long-term (Bhaskar, Dulhunty et 
al. 2012; Shaw, Johnson et al. 2013; Shaw, Johnson et al. 2013). Two separate analyses 
of 30-day outcomes of CABG showed transfusions were associated with increased 
short-term mortality, post-operative MI, new onset arrhythmias, stroke, and organ failure 
(Bhaskar, Dulhunty et al. 2012; Shaw, Johnson et al. 2013). Other studies have linked 
administration of blood products to increased complication rates, increased risk for low- 
output heart failure, cardiac events, wound infection, and mortality in all cardiac 
procedures even in those patients deemed low-risk preoperatively (Surgenor, DeFoe et 
al. 2006; Bernard, Davenport et al. 2009; Surgenor, Kramer et al. 2009; Mohnle, 
Snyder-Ramos et al. 2011; Bhaskar, Dulhunty et al. 2012). In addition, the use of blood 
products was associated with increased 30-day complications and operative mortality 
regardless of HCT, especially at higher (>42%) HCT levels where transfusion was
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linked to a 2.5-fold increased risk for mortality (Shaw, Johnson et al. 2013). 
Furthermore, transfusions in cardiac surgery have been shown to be associated with as 
high as a 70% increase in late-mortality (Engoren, Habib et al. 2002; Koch, Li et al. 
2006; Surgenor, Kramer et al. 2009; Shander, Javidroozi et al. 2011; Bhaskar, Dulhunty 
et al. 2012). In the long-term, the amount of blood used and type of blood affects 5-year 
mortality. Previous studies have demonstrated up to an 18% 5-year mortality rate in 
patients who received a blood transfusion, with significant differences in survival 
materializing after just two years (Bhaskar, Dulhunty et al. 2012; Shaw, Johnson et al. 
2013). Out of all blood products, cryoprecipitate transfusion was linked to a 2-fold 
increased risk of mortality. These short- and long-term effects are apparent even in 
patients that receive 1 or 2 units of blood, regardless of type of cardiac procedure 
(Surgenor, Kramer et al. 2009). The effect of transfusion in elderly patients (>80 years 
old) is disputed, with evidence for and against the administration of blood (Surgenor, 
DeFoe et al. 2006; Surgenor, Kramer et al. 2009; Veenith 2010; Yun 2012).
Risks o f Transfusions
There are additional hazards of transfusions beyond an overall decrease in 
survival. It is estimated that 51,000 patients suffered a transfusion-related reaction in the 
United States leading to a rate of 2.4 reactions per 1,000 units (Whitaker 2011). The 
risks associated with transfusion fall into two categories: transfusion-transmitted 
infections (TTI) (such as HIV or hepatitis) or noninfectious complications. With 
improved screening and awareness protocols, the risk for TTI has fallen dramatically in 
the past 20 years; however the discovery of new infectious agents such as prions, the
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causative agent of Creutzfeld-Jacob disease, and the dengue virus reveals new risks for 
TTI (Bihl, Castelli et al. 2007; Stramer, Hollinger et al. 2009; Squires 2011).
Noninfectious complications include acute transfusion reactions, transfusion- 
related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), 
transfusion-associated dyspnea and delayed transfusion reactions (such as delayed 
hemolytic reaction, post-transfusion purpura, and transfusion-associated graft-versus- 
host disease (TA-GVHD))(Wintrobe and Greer 2004; Toy, Popovsky et al. 2005; Bux 
and Sachs 2008; Squires 2011). It is believed that the incidence of noninfectious 
complications are under-diagnosed and under-reported (Shander, Javidroozi et al. 2011).
Acute transfusion reactions include allergic, hemolytic, hypotensive, and febrile 
reactions. Allergic and hemolytic reactions are similar and are the result of the 
recipient’s immune system attacking a substance in the blood (allergic) or the blood 
cells themselves (hemolytic). The symptoms of an allergic reaction to blood transfusion 
are similar to any allergic reaction and tend to be mild (hives and itching), but more 
serious reactions (such as anaphylaxis and tachycardia) have been documented (Lin, Ho 
et al. 1990; Shanthi, Bhavanadhar et al. 2013). Hemolytic reactions are most commonly 
caused by mismatched blood types such as administering Type A blood to someone that 
is Type B. Blood type is determined by which form(s) of glycophorin is found (or not 
found, in the case of Type O) on the extracellular cell wall of the red blood cell (RBC). 
The immune system of the recipient will attack the donor blood cells, which will result 
in the destruction of the donor erythrocytes in addition to the aforementioned allergic 
response (Wintrobe and Greer 2004). Acute hypotensive transfusion reactions (AHTR) 
are the result of a buildup of bradykinin in the blood (Kalra, Palaniswamy et al. 2012).
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Bradykinin production is increased when Factor Xlla is exposed to the negatively 
charged surface of the blood filter. Typically, bradykinin is normally broken down by 
angiotensin converting enzyme (ACE), which is responsible for 75% of bradykinin 
inactivation. Febrile reactions are defined as an unexplained fever or chills in a patient 
who is receiving or has received a transfusion within six hours (Baldwin 2002). The 
reaction is caused by an accumulation of cytokines produced during blood product 
storage; therefore febrile reactions can be avoided by filtering out cytokines in the donor 
blood or prevention of cytokine formation (Heddle 1999).
TRALI, TACO, and transfusion-associated dyspnea are very similar conditions. 
TRALI, characterized by hypoxemia, decreased blood pressure, and pulmonary edema, 
is a potentially fatal reaction to blood transfusion (Toy, Popovsky et al. 2005; Squires 
2011). It is estimated that 1 out of every 5,000 patients receiving a RBC transfusion will 
develop TRALI within 2 hours (Wintrobe and Greer 2004; Toy, Popovsky et al. 2005). 
The development of TRALI is associated with neutrophil activation either by the 
presence of leukocyte antibodies, cytokines, or other biologically active substances in 
the donor blood (Toy, Popovsky et al. 2005; Squires 2011). Improved donor blood 
filtering techniques have reduced the appearance of TRALI (Yazer, Podlosky et al. 
2004). TACO also presents with pulmonary edema, but in this condition, blood pressure 
and heart rate are increased (Squires 2011). Another distinguishing factor between 
TRALI and TACO is the response to diuretic therapy: it is ineffective in TRALI but 
rapidly reduces TACO (Squires 2011). If TRALI and TACO are ruled out in the setting 
of pulmonary edema after transfusion, the patient is diagnosed with transfusion- 
associated dyspnea (Bux and Sachs 2008).
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As the name suggests, delayed transfusion reactions present themselves 5 days to 
3 weeks after transfusion. Some are similar to acute reactions, such as delayed hemolytic 
reaction (although the delayed version is much milder) (Wintrobe and Greer 2004). 
Post-transfusion purpura is rare condition where a patient develops thrombocytopenia 
(low platelet (PLT) count) 5-14 days after receiving blood products, resulting in 
uncontrolled bleeding (McCrae and Herman 1996; Wintrobe and Greer 2004). This 
sometimes fatal condition is caused by either the patient’s immune response to the donor 
blood or an anti-PLT antigen in the donor blood (McCrae and Herman 1996). 
Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD) occurs when donor T 
cells go unrecognized by the recipient, such as in a blood donation between family 
members or transfusion in immunocompromised patients (Wintrobe and Greer 2004). 
The graft T cells are then allowed to proliferate unhindered, where they then mount an 
immune response against the host within 2-3 weeks (Schroeder 2002). There is no truly 
effective treatment for TA-GVHD, therefore the disease is associated with a 90% rate of 
mortality (Schroeder 2002; Wintrobe and Greer 2004).
Current Clinical Guidelines
Despite these known risks, there is still no standard protocol guiding blood 
transfusions in cardiac patients. This most likely stems from the lack of contemporary 
randomized prospective trials that address the role of blood products in general. In fact, 
the current Society of Thoracic Surgeons (STS) and The Society of Cardiovascular 
Anesthesiologists (SCA) clinical practice guidelines are largely based upon a trail that 
was performed in critical care patients in 1999 (Hebert, Wells et al. 1999; Ferraris,
5
Ferraris et al. 2007). In this study, Hébert et al. found that transfusing a patient with 
hemoglobin (HGB) level of <7 g/dL was associated with increased survival. On the 
other hand, an increase in mortality was noted when patients with HGB <10g/dL were 
given blood products. The STS/SCA also recommends the administration of red blood 
cells (RBC) in patients who have experienced uncontrolled blood loss or when they have 
lost more than l,500mL or >30% of their total blood volume, regardless of HGB levels. 
Collectively, this is referred to as the “ 10/30 Rule”, despite the fact that there has yet to 
be a study that demonstrated a clear benefit or consequence to transfusing those patients 
with HGB levels between 7 and 10 g/dL (Hebert, Wells et al. 1999; Ferraris, Ferraris et 
al. 2007; Ferraris, Brown et al. 2011). Other indications for administration of blood 
products include if the patient has chronic cardiovascular/pulmonary disease or HGB 
<6.0g/dL if on cardiopulmonary bypass (Ferraris, Ferraris et al. 2007). The STS/SCA 
concedes that these transfusion triggers are based upon very limited (mostly 
observational) studies and therefore require more empirical evidence (Ferraris, Ferraris 
et al. 2007; Ferraris, Brown et al. 2011). There is a recent randomized study from Brazil 
that focused on a small group of cardiac surgery patients (Hajjar, Vincent et al. 2010). In 
this single-center study, Hajjar et al. (2010) found no difference in mortality between a 
liberal transfusion trigger (<30% hematocrit, HCT) and a restrictive strategy (<24% 
HCT).
Perhaps due to the lack of solid evidence, cardiac surgery transfusion rates vary 
wildly between institutions (Maddux, Dickinson et al. 2009; Bennett-Guerrero, Zhao et 
ah 2010). In CABG patients, transfusion rates range from 7.8% to 92.8% for packed 
RBCs, 0% to 97.5% for fresh-frozen plasma, and 0.4% to 90.4% for PLTs in the United
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States (Bennett-Guerrero, Zhao et al. 2010). Furthermore, there has been only minimal 
change in transfusion rates for cardiovascular procedures since the transfusion 
guidelines were published in 2007 (Bennett-Guerrero, Song et al. 2010). A recent survey 
of several American and Canadian anesthesia and perfusion societies revealed that only 
22% of anesthesiologists and 33% of perfusionists had even read the guidelines 
(Varghese and Myers 2010). In addition, the new guidelines were recognized by only 
20% of institutions (Varghese and Myers 2010).
A blood transfusion can be life-saving in some situations such as extreme blood 
loss, but most cardiac surgery patients are not in hemorrhagic shock. Furthermore, most 
experts agree that a blood transfusion is either uncertain or unlikely to improve 
outcomes in most common clinical scenarios (Shander A. 2011). In addition, several 
studies investigating Jehovah’s Witness patients (who cannot accept blood transfusions) 
and strict blood conservation programs have demonstrated that patients can safely 
undergo cardiac surgery with minimal to no blood use and without increased risk for 
complications and/or mortality (Shander, Moskowitz et al. 2005; Stamou, White et al. 
2006; Moskowitz, McCullough et al. 2010; Varghese and Myers 2010; Weltert, Nardella 
et al. 2012).
Cost o f Transfusion
In addition to the clinical risks in blood transfusion, there is a significant cost to 
be considered when deciding to give blood products to a patient. In 2011, the American 
Red Cross spent nearly $2.2 billion on biomedical services, a figure that includes all the 
costs associated with collection, processing, testing, and distribution of blood products
7
nationwide (Cross 2011). Shander et al (2010) showed the mean total cost per RBC unit 
was $760.82 ± $293.74, with hospitals in the northeast United States having the highest 
costs(Shander, Hofmann et a l 2010). While the first priority of a medical institution is 
to provide the best care possible to patients, it is also a business and therefore, the cost 
of a procedure must be taken into account.
Anemia
While RBC administration is the fastest method to raise HGB levels, the effects 
of transfusions on muscle oxygenation and microvascular activity are inconsistent and 
unpredictable (Creteur, Neves et al. 2009; Shander, Javidroozi et al. 2011). Rather, most 
post-surgical patients are given blood products with the thought that it will treat post- 
surgical anemia, ultimately leading to improved patient recovery (Bhaskar, Dulhunty et 
al. 2012). However, these transfusions may not be necessary as the body can compensate 
for anemia remarkably well. An individual’s response to anemia depends on many 
factors and, as a consequence, can vary amongst patients (Shander, Javidroozi et al.
2011). In a healthy patient, normal tissue oxygenation can be achieved with a HGB level 
of 6g/dL and a HCT of at least 15% (Doak and Hall 1995). Increased mortality was only 
seen once HGB levels fell below 5g/dL and/or HCTs below <14% (this raises to 17% in 
high-risk patients) (Fang, Helm et al. 1997). The lowest reported HGB level in a 
surviving non-transfused patient is 0.7 g/dL(Dai, Tu et al. 2010). Low HCT level during 
surgery have been associated with increased risk for in-hospital mortality, peri-operative 
placement of an intraaortic balloon pump, and failure to separate from cardio-pulmonary 
bypass (DeFoe, Ross et al. 2001). At a physiological level, minimum levels for proper
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tissue oxygenation are HGB levels 4 g/dL, an oxygen extraction ratio of 0.44, a mixed 
venous oxygen of 34 mm Hg, and a mixed venous oxygen saturation of 56%; tissues 
become insufficiently oxygenated below these values (Weisel, Charlesworth et al. 
1984). While it is likely higher for the cardiovascular surgery patients, the mean HGB 
level for anemia-induced mortality is 2.5 g/dL (Weiskopf 2010).
This is likely because there are many compensatory mechanisms to manage 
anemia in the body (Shander, Javidroozi et al. 2011). For instance, in situations where 
oxygen is unavailable, erythropoiesis, angiogenesis, and anaerobic metabolism are 
increased in the cells. Furthermore, the lungs raise the partial pressure of blood oxygen 
by releasing more nitric oxide and increasing respiration rate, thus increasing HGB-O2 
saturation. The body will also increase cardiac output, blood viscosity, systemic 
vasodilation, and venous return to maintain tissue oxygenation levels. Furthermore, 
oxygen extraction increases in select organs, with the highest priority given to the brain 
and the heart. Interestingly, the long-term consequences of anemia are similar to that of 
transfusion, with higher mortality rates and increased risk of fractures, renal disease, 
heart failure, cardiovascular events, réadmissions, poorer graft outcome, worse 
functional status, and lower quality of life (Shander, Javidroozi et al. 2011).
In a non-urgent case, anemia can be successfully and quickly treated with 
hematinic medications (Szlyk, King et al. 1984). In addition, recent studies have shown 
treatment of anemic patients with pre-operative erythropoietin plus iron has decreased 
the need for peri-operative transfusions by almost 30% in valve replacement surgeries 
(Cladellas, Farre et al. 2012). A combined pre-operative treatment of erythropoietin and 
iron was found to be associated with 30-day survival and shorter post-operative hospital
stay, although it the use of iron did not reduce the need for transfusion (Garrido-Martin, 
Nassar-Mansur et al. 2012). Post-operative low-dose aprotinin has also been shown to 
reduce the need for transfusion after cardiac surgery (Mansouri, Attary et al. 2012).
Blood Biochemistry
Blood, in the most basic sense, is made up of two major parts: the liquid plasma 
and the cells that are suspended in it. If the clotting factors are removed from the plasma, 
it is referred to as serum (Powar, Chatwal et al. 2008). There are three cell types 
commonly found in blood: the oxygen- and nutrient carrying erythrocyte (or RBC), the 
infection-fighting leukocytes (or white blood cells, WBC), and the vascular wall 
repairing PLT. Collectively, they make up 40-45% of the blood; this percentage is also 
referred to as the HCT (Powar, Chatwal et al. 2008). All blood cells are formed from 
hematopoietic stem cells found in the bone marrow( Jane way 2001; Turgeon 2005).
The anucleated RBC are 6-9 pm wide, biconcave discs that are formed in the bone 
marrow (Powar, Chatwal et al. 2008; Hall, Guyton et al. 2011). Their characteristic red 
color comes from oxygen binding to their ferrous [Fe2+] iron-containing HGB; in the 
absence of oxygen, the cells appear blue-violet. HGB is an important component of 
blood and will be discussed in more detail elsewhere. The RBC cell membrane, like 
most cells, is semi-permeable and allows water, CO2, urea, glucose and other small non­
ionic molecules through (Powar, Chatwal et al. 2008). In addition, certain ions such as 
bicarbonate (HCO3'), chloride (Cf), hydroxide (OH'), and potassium (K+) can freely 
pass through the membrane. The RBC is not permeable to magnesium (Mg2^ ), but the 
cation is found inside the cell (Powar, Chatwal et al. 2008). While they contain no
10
mitochondria, the RBCs will breakdown glucose (albeit very slowly) in order maintain 
its cell membrane and prevent the accumulation of methemoglobin (metHGB) (a 
condition known as methemoglobinemia) (Ash-Bernal, Wise et al. 2004; Powar,
Chatwal et al. 2008). metHGB contains ferric [Fe3+] iron, which does not bind oxygen as 
readily as ferrus iron; this results in decreased oxygen-carrying capacity (Ash-Bernal, 
Wise et al. 2004). RBC also contain large quantities of carbonic anhydrase in order to 
catalyze the reaction between water and CO2 to form HCO3', which allows the plasma to 
transport CO2 away from the tissues to the lungs to be exhaled (Hall, Guyton et al.
2011). Males have 5.2 million RBCs per mm3 of blood while females have slightly less 
at 4.7million/mm3 (Hall, Guyton et al. 2011). The average RBC breaks down after four 
months and is filtered out of the blood by the spleen or liver (Powar, Chatwal et al. 
2008). RBCs have been shown to become fragmented in patients with valvular disorders 
and surgeries, especially those receiving a prosthetic valve, likely due to turbulent flow 
(Wintrobe and Greer 2004).
There are many differences between RBC and WBC. WBC are more active type of 
cell that contains a nucleus and are able to move on their own (Powar, Chatwal et al. 
2008). In fact, WBC can leave the blood vessels in order to move to the site of an 
infection or injury. Most WBC are phagocytic and will engulf bacteria or dead cells that 
are then broken down by proteins in the WBC cytoplasm (Powar, Chatwal et al. 2008). 
There are five types of WBC: bacteria- and fungi-fighting neutrophils, histamine­
releasing basophils, parasitic-fighting and allergy modulating eosinophils, the acquired 
immune system-mediating lymphocytes (not commonly found in the blood), and the 
large macrophage monocytes (Alberts 2002).
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PLTs are formed by fragmentation of the megakaryocytes as they are released 
from the bone marrow (Hall, Guyton et al. 2011). PLT aggregation is the first step in 
repairing cuts or lesions in the vascular endothelium (Hall, Guyton et al. 2011). PLTs 
are not fully functional cells, yet their purpose is integral to vascular repair. Their 
extracellular membranes are coated in glycoproteins that allow the PLTs to bind to the 
collagen that exposed when a vessel is injured, allowing the PLTs to identify sites of 
vascular injury (Hall, Guyton et al. 2011).
Plasma is essentially a water solution containing certain salts (ex. NaCl and 
NaHCOs), proteins (such as albumin (ALB), fibrinogen, etc.) and antibodies, hormones, 
glucose and amino acids from digested food, and waste products such as CO2 and urea 
(Powar, Chatwal et al. 2008). Proteins make up a bulk of the solids in the plasma 
(accounting for ~7-9g per 100 mL of blood) and can be separated via electrophoresis, 
ultracentrifugation, and ethanol fractionation (Powar, Chatwal et al. 2008).
Components o f Clinical Hematological Analyses and Their Roles
Blood plays two basic roles in the body: transportation of materials and 
maintaining homeostasis. Blood is responsible for transporting oxygen from the lungs to 
the tissues, carbon dioxide from the tissues to the lungs, nitrogenous waste from the liver 
to the kidneys, hormones throughout the body, the products of digestion from the ileum 
to the tissues, WBCs to protect the body from infection. Through this transportation, 
blood provides the tissues with the materials necessary to maintain an optimal 
environment (Powar, Chatwal et al. 2008). In addition, blood also plays a role in the 
distribution of heat throughout the body. Many of these functions are analyzed in the
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clinical setting via blood tests. This study examines the results of four common blood 
analyses (Chemistry, Coagulation, Cardiac/Critical Care and Hematology) representing 
33 variables overall. These tests are performed multiple times throughout the patient’s 
hospital course. The normal range for each measure can be found in Table 1.
Table 1: The blood components and characteristics analyzed by standard blood tests.
Variable Normal Clinical 
Range
Basic Function Clinical
Relevance
Chemistry
Calcium 8.4-10.2 mg/dL Secondary 
messenger, 
enzyme cofactor, 
various other roles
Kidney, 
cardiovascular, 
and neurologic 
function
Glucose 70-110 mg/dL Metabolism Diabetes, liver 
function
Blood Urea 
Nitrogen
6-20mg/dL Transport of urea 
to kidneys
Kidney function
Creatinine 0.5-1.2 mg/dL Muscle
metabolism
Kidney function
Sodium 135-145 mmol/L Osmoregulation,
muscle
contraction, and 
neuronal firing
Osmoregulation
Potassium 3.3-51. mmol/L Muscle contraction 
and neuronal firing
Kidney function
Chlorine 95-108 mmol/L Counter-ion Kidney function
C 0 2 22-29 mmol/L Oxygen/carbon 
dioxide transport
Oxygen/ C 0 2 
transport
Coagulation
Prothrombin 11-14.5 sec Time to activate Measure of
Time clotting coagulability & 
liver function
International 0.9-1.3 Deviation in Measure of
Normalized clotting time from coagulability &
Ratio normal liver function
Activated Partial 21-37.5 sec Time to activate Measure of
Thrombo-plastin
Time
clotting coagulability & 
liver function
Cardiac/Critical
Care
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PH 7.35-7.45 Maintenance of
extracellular
environment,
influences
oxygen/carbon
dioxide transport
O2/CO2 transport
pC 02 35-45 mmHg Influences 
oxygen/carbon 
dioxide transport
O2/CO2 transport
p02 80-105 mmHg influences O2/CO2 transport
oxygen/carbon
dioxide transport
Bicarbonate 18-23 mmol/L Oxygen/carbon O2/CO2 transport
(HCO3-) dioxide transport,
counter-ion
O2 Saturation 95-100% Amount of O2 O2/CO2 transport
carried by blood
Hematology
White Blood 4.50-10.5 k/mm3 Immune response Measure of
Cell Count infection
(WBC) ........................ .... ..._ ............. -... .1.. . .... ...|
Red Blood Cell 4-5.4 m/mm3 Oxygen transport O2/CO2 transport,
Count (RBC) identifies anemia
Hemoglobin(HG 12-16 g/dL Oxygen transport O2/CO2 transport
B)
Hematocrit 36-48% Cell to Plasma O2/CO2 transport,
(HCT) Ratio identifies anemia
Mean 80-95 fL Size of RBC Identifies anemia
Corpuscular
Volume (MCV)
Mean 27-31 pg Average mass of O2/CO2 transport,
Corpuscular HGB in RBC identifies anemia
Hemoglobin
(MCH)
Mean 32-36 g/dL HGB O2/CO2 transport,
Corpuscular Concentration in Identifies anemia
Hemoglobin RBC
Concentration
(MCHC)
Red Blood Cell 11.5-14.5% Measures variance Identifies anemia
Distribution of RBC size
Width (RDW)
Platelet Count 150-450 k/mm3 Initiates Measure of
(PLT) coagulation coagulability
Mean Platelet 7.4-10.4 FL Size of PLT Measure of platelet
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Volume (MPV) health
Chemistry
The Chemistry test reveals the ion and protein content of the blood. The studied 
metabolites are: calcium (Ca2+), blood glucose (GLU), blood urea nitrogen (BUN), 
creatinine (CR), sodium (Na+), potassium (K+), chlorine (Cf), and carbon dioxide (CO2, 
discussed in Cardiac/Critical Care).
The electrolytes Ca2+, Na+, K+, and C f have a well-defined role in neuronal 
conduction and muscle contraction as well as maintaining electrical, osmotic, and 
concentration gradients. Calcium is a known second messenger in many chemical 
pathways, such as those involved in PLT activation and T-cell activation (Heemskerk, 
Bevers et al. 2002; Wintrobe and Greer 2004). Calcium also acts a co-factor of many 
enzymes, including those involved in blood clotting, such as Factor X and Prothrombin 
(Hall, Guyton et al. 2011). Hypocalcemia is rare under normal conditions, but in 
situations of extreme blood loss or ion-quenching with citrate or oxalate, active calcium 
levels can fall enough to affect enzyme kinetics (Hall, Guyton et al. 2011). 
Hypocalcemia can be found secondary to myocardial infarction (MI), sepsis, renal 
insufficiency, and/or hemorrhagic shock (Marino 1998; Whitted, Stanifer et al. 2010). 
Hypocalcemia can cause neurologic (hyperreflexia, seizures, and tetany) and 
cardiovascular (hypotension, lowered cardiac output, and ventricular arrhythmias) issues 
(Marino 1998). Hypercalcemia is rare and only develops in 1% of patients (Marino 
1998). However, patients can develop hypercalcemia after surgery with 
cardiopulmonary bypass (Westhorpe, Varghese et al. 1978). Increased serum calcium 
can lead to kidney stones, neurologic dysfunction, polyuria, renal failure, and coma
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(Reagan, Pani et al. 2013). Interestingly, hypercalcemia can also disrupt 
electrocardiograms, making it appear as if a patient has had a MI (Wesson, Suresh et al. 
2009; Reagan, Pani et al. 2013).
Sodium in the blood plasma drives osmolality of the extracellular fluid (Marino 
1998). Due to this, sodium can be thought to maintain the relative extra- and 
intracellular volumes. The most common cause of hypernatremia (high blood sodium) is 
loss of low sodium fluids such as urine, sweat, and diarrhea (Marino 1998). Higher 
concentrations of sodium in the plasma draws water out of the RBCs, causing 
hypovolemia and decrease oxygen transport. Hypernatremia can indicate water 
intoxication, syndrome of inappropriate anti-diuretic hormone (a marker of tumors 
and/or infections), and heart, renal, and hepatic failure (Marino 1998). If untreated, 
hypernatremia can result in irreversible and potentially fatal brain damage due to 
cerebral edema (Marino 1998).
Only 2% of potassium in the body is found in the plasma (Marino 1998; 
Wintrobe and Greer 2004). Intracellular potassium is of particular importance to the 
heart; being a muscle, heart contraction is dependent on potassium to maintain the 
resting membrane potential In hypokalemia, the already low levels of serum potassium 
fall even further, causing hyperpolarization, elongated heart contraction, and delayed 
myocardial repolarization(Whitted, Stanifer et al. 2010). Due to this, hypokalemia is 
associated with the development of cardiac arrhythmias (in patients with digitalis and/or 
magnesium depletion), muscle weakness, and mental status changes (Marino 1998; 
Whitted, Stanifer et a l  2010). Hypokalemia can also indicate alkalosis (basic blood, 
plasma pH >7.4), diarrhea, and/or hypothermia (Marino 1998). While hypokalemia can
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be easily tolerated, hyperkalemia is very serious and potentially fatal. Increasing 
extracellular potassium causes an increasingly slower heart rate and at high enough 
concentrations can cause the heart to stop completely; this is why potassium chloride is 
used for lethal injection in the United States (Marino 1998; Khanna and White 2009). 
Hyperkalemia in heart failure patients is commonly caused by renal insufficiency, 
massive blood transfusions (replacing more fluid than what was lost), and use of the 
anti-hypertensive medications angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers (Marino 1998; Khanna and White 2009).
Chloride is generally thought of as a counter-ion (along with HCO3') to 
neutralize the charges of the serum cations. Increased diuresis and/or alkalosis can cause 
a loss of Cl' (hypochloremia), leading to an increase in serum HCO3' levels to 
compensate (Marino 1998). Patients with hypochloremia have been shown to spend 
more time in the intensive care unit. Hyperchloremia can be caused by administration of 
saline during surgery, renal failure, or diarrhea(McCluskey, Karkouti et al. 2013). Both 
hypo- and hyperchloremia have been associated with increased in-hospital mortality, 
however both conditions are relatively well-tolerated (Boniatti, Cardoso et al. 2011;
Tani, Morimatsu et al. 2012; McCluskey, Karkouti et al. 2013).
Glucose is strictly monitored throughout a patient’s hospital stay, Aside from its 
aforementioned role in maintaining the RBC membrane, glucose is used throughout the 
body as a source of chemical energy. However, too much (hyperglycemia, >180mg/dL) 
or too little (hypoglycemia <60mg/dL) glucose post-cardiac surgery has been associated 
with poor outcomes (Hermanides, Bosman et al. 2010; Haga, McClymont et al. 2011; 
Stamou, Nussbaum et al. 2011). Furthermore, the stress of the surgery itself causes
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patients to become hyperglycemic (McCowen, Malhotra et al. 2001). Glucose levels are 
also elevated in patients with liver failure and diabetes (Wintrobe and Greer 2004). 
Diabetes is a major risk factor in cardiac surgery and is associated with increased short- 
and long-term mortality, stroke, and infection (Furnary, Zerr et al. 1999; Thourani, 
Weintraub et al. 1999; Lazar, Chipkin et al. 2004). Through tight or moderate glycemic 
control, it is possible to reduce the risk of hyper- and hypo-glycemia (Leibowitz, 
Raizman et al. 2010; Bhamidipati, LaPar et al. 2011; Haga, McClymont et al. 2011; 
Stamou, Nussbaum et al. 2011). By giving insulin to keep their blood glucose within 
127-179 mg/dL (moderate control), patients suffered less infection, lower length of stay, 
and fewer incidences of recurrent ischemic attack, especially in those with diabetes 
(Furnary, Zerr et al. 1999; Lazar, Chipkin et al. 2004; Leibowitz, Raizman et al. 2010; 
Bhamidipati, LaPar et al. 2011; Haga, McClymont et al. 2011; Stamou, Nussbaum et al. 
2011). Uncontrolled hyperglycemia can result in hypovolemia, hypertonic 
encephalopathy, and ketoacidosis (Marino 1998).
BUN and CR are markers of renal function. Concomitant renal and heart failure 
is known as cardiorenal syndrome and is associated with reduced cardiac output, 
increased systemic blood pressure, and fluid overload (Aronson 2012). As the kidneys 
decompensate, less urine is produced and more urea is found in the blood (Kazory 
2010). Of particular relevance to the current study, a BUN >43mg/dL is significantly 
associated with in-hospital mortality in heart failure patients (Kazory 2010). Elevated 
BUN is also a marker for gastrointestinal bleeding (Sleisenger, Feldman et al. 2010). 
Creatine is found in muscles and is a source of adenosine triphosphate (ATP) during 
intense energy demand (Wyss and Kaddurah-Daouk 2000). When creatine is broken
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down, it is converted to CR. CR circulates through the blood to the kidneys, where it is 
filtered out and excreted in the urine; however, if there is an issue in the kidney, CR will 
go back into the bloodstream (Wyss and Kaddurah-Daouk 2000). Thus, serum CR is 
inversely related to renal function. An increase in CR in the blood of greater than 10% is 
predictive of acute kidney injury; an increase of 25% is associated with a two-fold risk 
of mortality (Ho, Reslerova et al. 2012). On the other hand, a decrease in CR after 
surgery is associated with improved survival (Lassnigg, Schmidlin et al. 2004). 
Interestingly, the predictive performance of CR for renal function is strongest in patients 
with severe heart failure (Smilde, van Veldhuisen et al. 2006). CR >1.5mg/dL is also 
associated with hepatorenal syndrome (Sleisenger, Feldman et al. 2010). In this disease, 
failure of the liver and kidneys compromises the other and can even result in lower 
cardiac output (Sleisenger, Feldman et al. 2010). Elevated CR is also a marker for 
gastrointestinal bleeding (Sleisenger, Feldman et al. 2010). It is important to note that 
BUN has been shown to be the more reliable predictor of renal function and cardiac- 
related complications than CR(Kazory 2010; Beier, Eppanapally et al. 2011; Aronson 
2012).
Coagulation
The Coagulation characteristics -prothrombin time (PT), international 
normalized ratio (INR), and activated partial thromboplastin time (aPTT) are used to 
evaluate the clotting characteristics of the blood. If the blood does not clot, there is a 
high risk for bleeding; however, if clots form too readily, the patient has a high risk for 
thrombosis and stroke. PT is generated by measuring the time it takes blood to clot via
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the extrinsic pathway, representing the conversion of prothrombin to thrombin in the 
presence of calcium and tissue factor (Turgeon 2005; Hall, Guyton et al. 2011). 
However, PT time is difficult to standardize due to variation from test to test and system 
to system. In order to address this, the INR was developed. The INR develops a ratio
power of the international sensitivity index, which is a manufacturer-generated 
assessment of the tissue factor used in the analysis (Hall, Guyton et al. 2011).
aPTT is yet a third way to measure coagulation factors, although this assay reflects the 
intrinsic coagulation pathway via the activity of prekallikrein, high-molecular weight 
kininogen, and Factors I, II, V, VIII, IX, X, XI, and XII (Turgeon 2005). A short or long 
aPTT is indicative of too little or too many, respectively, of these factors or the presence 
of an anticoagulant (Turgeon 2005). As the liver is responsible for the synthesis of 
coagulation factors, the PT, INR, and aPTT will all be elongated in patients with liver 
disease (Turgeon 2005).
Hematology
The Hematology variables look at the physical makeup of the blood and its 
component parts. These include: WBC count, RBC count, HGB, HCT, mean 
corpuscular volume (MCV), mean corpuscular HGB (MCH), MCH concentration 
(MCHC), RBC distribution width (ROW), PLT count, and mean PLT volume (MPV).
The role of HGB is to transport oxygen to the tissues throughout the body. HGB 
is a heme-containing protein that binds oxygen to form oxyhemoglobin, an unstable
from the results of the current PT test to a control sample; this ratio is then raised to the
P f  I SI
* 1 test \
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molecule that readily breaks down in environments of low partial pressure oxygen 
(Powar, Chatwal et al. 2008). Interestingly, the four subunits that make up HGB 
demonstrate cooperative (or allosteric) binding (Wintrobe and Greer 2004). This forms a 
sigmoidal oxygen dissociation curve, which is displayed in Figure 1. It is this 
relationship that allows HGB to carrying oxygen from the 02-rich lungs to the 02- 
deficient tissues. HGB’s role as oxygen transporter is what makes it so important. When 
a patient is given donor RBC, HGB level quickly rise; a study found HGB levels to rise 
by 1.3 g/dl and in oxygen delivery to increase 50ml/minute/m after a transfusion 
(Creteur, Neves et al. 2009). However, there was no corresponding significant increase 
in oxygen saturation or consumption (Creteur, Neves et al. 2009).
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Figure 1 : The Oxygen Dissociation Curve. The partial pressure of oxygen (pÛ2) drives 
oxygen binding and dissociation from hemoglobin. The sigmoidal shape is due to the 
cooperative binding effect of the four subunits in hemoglobin. (Adapted from (Wintrobe 
and Greer 2004))
As previously stated, the HCT is the % volume of cells in whole blood. It has 
been shown that the lower a patient’s HCT goes during surgery, the higher risk for post­
operative complications (DeFoe, Ross et al. 2001). Patients with anemia will have a low 
HCT; likewise, erythrocytosis (overproduction of RBCs) results in raised HCT. Blood 
viscosity increases exponentially with HCT which leads to reduced blood flow and, 
consequently, decreased oxygen delivery (Wintrobe and Greer 2004). Previous work at 
the study location revealed that the most patients were discharged with HCT between 
28.5-31.3%, regardless of baseline HCT (Shaw, Johnson et al. 2013). This was thought 
to be indicative of a target discharge HCT and that the patient would be transfused to 
reach this target, despite lack of evidence or support for this practice (Shaw, Johnson et 
al. 2013).
The MCV, MCH, and MCHC are used to measure the size and HGB content of 
RBCs. Since the 1930’s, they have been used to characterize anemias (Brugnara and 
Mohandas 2013).
MCV =
HCT (q)
RBC count (— j— )
MCH =
HGB (X —jf f —) 
1012RBC count
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HGB
MCHC = — —
HCT
MCV tends to increase as a person ages with no apparent relation to anemia 
(Gamaldo, Ferrucci et al. 2011). Most automated hematology analyzers (like the one 
used in this study) use MCV to generate HCT (Brugnara and Mohandas 2013). By 
comparing MCV and MCH, it is possible to distinguish between certain kinds of 
anemia, such as p-thalassemia (a genetic disorder requiring transfusions) and iron 
deficiency anemia (a relatively treatable condition). While both conditions result in 
decreased MCV and MCH, patients with P-thalassemia will have an increased number 
of small RBCs (microcytic RBCs) than hypochromic (HGB-deficient); however, this 
relationship is reversed (more hypochromic than microcytic) in iron deficiency anemia 
(d'Onofrio, Zini et al. 1992). Interestingly, iron deficiency will affect MCHC and MCH 
first and only influence MCV and RDW later on (Patton, Cave et al. 1991). In addition, 
low MCV (<80fL) can indicate a chronic gastrointestinal bleed, while a high MCV 
(>100fL) is suggestive of chronic liver disease (Sleisenger, Feldman et al. 2010).
A more recently developed measure, the RDW, can also be used to characterize 
anemias (Turgeon 2005; Brugnara and Mohandas 2013). RDW is a coefficient of 
variation percentage, representing the most commonly found RBC volume by excluding 
the extreme volumes at the low (likely clumped PLTs) and high end (clumped RBC) 
(Turgeon 2005).
RDW =
Standard Deivation  
Mean RBC Size
x  100%
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While a low RDW has not been linked to any abnormalities, a high RDW is associated 
with anemia and iron insufficiency, vitamin B12, and/or folic acid (Turgeon 2005).
Taken together, RDW and MCV can offer insight into the status of the erythrocytes; for 
instance, a high RDW and a low MCV indicate iron-deficiency anemia while a high 
RDW and a high MCV suggest a megoblastic anemia (Turgeon 2005). However, the 
efficacy of this method has been contested in literature (Flynn, Reppun et al. 1986; 
Brugnara and Mohandas 2013). Of particular note to the current study, RDW is 
associated with mortality in patients with heart failure, MI, and/or in the intensive care 
unit (as in after surgery) (Forhecz, Gombos et al. 2009; Borne, Smith et al. 2011; Wang, 
Pan et al. 2011; Wang, Hua et al. 2011). In elderly patients, a 1% increase in RDW is 
correlated with as much as a 14% increased risk of mortality (Semba, Patel et al. 2010). 
It is hypothesized that increased RDW is a result of inflammation, oxidative stress, 
and/or vascular injury (Semba, Patel et al. 2010; Brugnara and Mohandas 2013).
The role of PLTs in healthy physiology has been previously discussed. However, 
deviations from normal PLT values can have disastrous consequences. For instance, if 
there are too few PLTs (thrombocytopenia), vascular injury can go untreated resulting in 
uncontrolled bleeding. Of particular relevance to the current subject, thrombocytopenia 
can occur as a result from using cardiopulmonary bypass in surgery (Schmidt, Peden et 
al. 1961; Turgeon 2005). On the other hand, if there are too many PLTs in the blood 
(thrombocytosis), they could form a clot (a thrombus) where it could block the vessel 
and lead to ischemia (a lack of oxygen to a given tissue). If the clot breaks off and 
travels through the blood stream, it is referred to as an embolus. Interestingly, 1-3% of 
patients can develop heparin-induced thrombocytopenia (HIT), an auto-immune disorder
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which can also lead to thrombus formation (Warkentin and Greinacher 2003; Turgeon 
2005). Heparin, an anti-anticoagulant commonly prescribed to cardiac surgeon patients, 
acts by binding to PLT factor 4; HIT occurs in those patients that form antibodies to this 
heparin-PLT factor 4 complex (Warkentin 2003; Turgeon 2005). While it will cause 
PLT levels to fall, the antibody-heparin-PLT binding will also increase the clotting 
abilities of the PLTs, leading to thrombosis formation in 30% of HIT patients; 25% of 
HIT thrombi are fatal (Turgeon 2005). In the absence of any other explanation, HIT 
should be suspected whenever there is a >50% decrease in PLT after exposure to 
heparin.
In a healthy patient, the volume of the average PLT shares an inverse 
relationship to the total amount of PLTs; that is, the more PLTs there are, the smaller 
each individual PLT is. Larger PLTs are more active enzymatically and more likely to 
generate a thrombus (Karpatkin 1969; Giles, Smith et al. 1994; Kamath, Blann et al. 
2001). Anti-coagulation with EDTA, which decreases PLT count, also causes PLTs to 
swell by almost 20% their normal volume for about 12 hours (Turgeon 2005). The 
formula for calculating MPV is similar to that for MCV (like HCT, plateletocrit is the 
percent volume of PLTs in the blood):
Plateletocrit
MPV  =  — — --------------
PLT count
Due to this variability of PLT volume, the range of an acceptable MPV depends on the 
patients’ PLT count; a MPV nomogram is generally used to determine the healthy range 
(Figure 2) (Turgeon 2005). A low MPV can indicate anemia and hypersplenism, while 
an elevated MPV after surgery is associated with an overproduction of blood cells, graft
25
failure and MI, and septic thrombocytopenia, in which a bacterial infection leads to the 
destruction of PLT (Giles, Smith et al. 1994; Turgeon 2005; Chu, Becker et al. 2010).
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Figure 2: Mean Platelet Volume Nomogram. Normal mean platelet volume varies with 
platelet count. (Adapted from (Pierre 1985)).
Cardiac/Critical Care
The variables covered under the Cardiac/Critical Care blood tests are: pH, pCC>2, 
pC>2, HCO3', and O2 saturation. In addition, these blood gas tests can be used to estimate 
serum Na+, K+, C1‘, Ca2+, and glucose levels.
The pH, pCC>2, and pC>2 of the blood affect oxygen and transport (Figure 3). As 
demonstrated in Figure 1, HGB’s oxygen affinity (the pC>2 at which 50% of HGB is 
bound to oxygen, P50) can be shifted to the right (decreased affinity) or the left
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(increased affinity); this change in affinity is known as the Bohr Effect. The tissues have 
high levels of CO2 and low pH, w-hich causes decreased oxygen affinity and HGB’s 
subsequent release of O2 into the tissues. The opposite is seen at the lungs, where pCCE 
is lower and pH is higher, resulting in increased oxygen binding. In addition, oxygen 
transport is also affected by pH and CO2 via CO2 binding to the A-terminus of HGB, 
forming carbaminohemoglobin. This causes a conformation shift which decreases the 
heme group’s O2 affinity (Wintrobe and Greer 2004). At a normal blood pH of 7.4, 
about 10% of HGB is normally found as carbaminohemoglobin; however this 
percentage increases in response to increasing acidity (Marino 1998; Wintrobe and 
Greer 2004).
Tissues Red Blood Cell Lungs
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Figure 3: Mechanism of Oxygen and Carbon Dioxide Transport in Red Blood Cells. 
HGB = hemoglobin, HCO3' = bicarbonate, HGBO2 = oxyhemoglobin, HHGB = 
protonated hemoglobin. (Adapted from (Wintrobe and Greer 2004)).
CO2 is not transported in the blood via carbaminohemoglobin, but rather as 
HCO3*. CO2 is converted to HCO3' via the following reversible reaction:
C02 +  H20  « - > H2C 0 3 <t* H C 0 2 + H +
The reaction equilibrium is dependent on the concentration of CO2, HCO3', and F f 
(Wintrobe and Greer 2004). CO2 passively diffuses into RBCs, where the formation of 
H2CO3 is catalyzed by carbonic anhydrase in the cells. Interestingly, the proton released 
by the breakdown into HCO3' is taken up by FIGB which reduces its affinity for oxygen 
(as demonstrated by the Bohr Effect) (Wintrobe and Greer 2004). The HCO3' diffuses 
out of the cell passively or by facilitated transport via ion exchange for CF. The HCO3' 
travels in the blood to the lungs, where the low pC02 drives the conversion back to CO2. 
CO2 dissociation is inversely affected by oxygen-bound HGB; this is known as the 
Haldane Effect (Figure 4). Higher concentrations of protons in the blood (acidosis) will 
cause hyperventilation to rid the body of CO2 and increased HCCV reabsorption in the 
kidneys; the reverse is true for alkalosis(Marino 1998). Due to increased fatty acid 
catabolism in diabetes, patients with this condition can develop ketoacidosis (Marino 
1998).
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pC02(mmHg)
Figure 4: Carbon Dioxide Dissociation Curve. CO2 content is dependent on pCC>2. The 
right shift due to HGBO2 concentration is called the Haldane Effect. HGBO2 = 
oxyhemoglobin (Adapted from (Wintrobe and Greer 2004)).
Goals
This study aims to track the physiological effects of blood transfusion after cardiac
surgery. This will be accomplished by retrospectively analyzing the trends in blood 
chemistry and blood characteristics over time in a series of propensity-matched 
transfused and non-transfused patients undergoing isolated CABG.
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CHAPTER 2
METHODS
Database Characteristics
Demographic data was collected from in a database certified by the STS. All 
variables were defined and coded using STS standards (Shahian, O'Brien et al. 2009; 
Overman, Jacobs et al. 2013; Shahian, Jacobs et al. 2013). Between July 2004 and June 
2011, 3,516 consecutive patients underwent cardiac surgery at The Valley Columbia 
Heart Center. In order to limit the confounding effects of additional treatments related to 
post-operative care, any patients with 30-day complications and/or mortality (defined 
using the STS standard definition of operative mortality as death within 30 days of 
surgery) were removed from this study (Overman, Jacobs et al. 2013; Shahian, Jacobs et 
al. 2013). This left a cohort of 1,134 patients that underwent an isolated CABG with no 
complications (Table 2). Of these, 407 (35.8%) patients received a blood transfusion.
Table 2: Overall Patient Characteristics
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Ejection Fraction 53.3 ±13.78 52.2 ±10.57
New York Heart 
Association 
Class III-IV
32 4.40% 129 31.70%
Renal Failure 20 2.75% 35 8.60%
Dialysis 2 0.28% 8 1.97%
Cardiogenic Shock 9 1.24% 6 1.47%
Intraoperative Blood 0 0.00% 142 34.89%
Postoperative Blood 0 0.00% 355 87.22%
Readmission Within 30
Days
23 3.16% 15 3.69%
Propensity-matching was used to provide a more balanced patient population 
(Rosenbaum 1983; Rosenbaum 1985; Rubin 1997). Using a logistic regression model, 
the probability of a patient receiving a blood transfusion was developed based upon 22 
baseline covariates that included gender, age, BMI, diabetes, smoking, hypertension, 
dyslipidemia, number of diseased coronary vessels, peripheral vascular disease, presence 
of heart failure, New York Heart Association (NYHA) class, history of stroke, chronic 
lung disease, MI history, renal failure, left main disease, left ventricular ejection 
fraction, CR, cardiogenic shock presentation, and urgent status. The resulting propensity 
scores were then employed to identify as many 1:1 matches between the transfusion and 
non-transfusion group using the nearest neighbor-matching algorithm with Greedy 5-1 
Digit Matching (Cormen 2001; Soriano 2012). The model produced a balanced cohort of 
636 patients: 318 transfused (TG) and 318 (NTG). The Society o f Thoracic Surgeons 
(STS) uses many of these categories to calculate a patient’s risk for post-surgical 
complications and mortality (Shahian, O'Brien et al. 2009; Jin, Furnary et al. 2010; 
Overman, Jacobs et al. 2013). STS Risk Adjusted Scores were calculated for each 
patient using eCardio (Velos, Fremont, CA), a STS-approved software. These scores
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were then used to generated predicted rates of overall morbidity and mortality, mortality, 
renal failure, need for re-operation, stroke, prolonged ventilation, deep sternal wound 
infection, and lengths of stay of greater than 6 and 14 days.
Data Collection
For each patient, 26 variables derived from traditional blood analyses 
(Chemistry, Coagulation, Cardiac/Critical Care, and Hematology) were collected (Table 
1, see page 13). These tests are performed multiple times throughout the patient’s 
hospital course except Cardiac/Critical Care, which is only performed in the intensive 
care unit. Each available measurement was recorded for each patient. The Chemistry 
metabolites were: Ca2+, GLU, BUN, CR, Na+, Kf, CF, and CO2. The Coagulation 
characteristics were PT, INR, and aPTT. The Hematology variables were: WBC, RBC, 
HGB, HCT, MCV, MCH, MCHC, RDW, PLT, and MPV. The variables covered under 
the Cardiac/Critical Care blood tests are: pH, pCC>2, p02, HCO3', and O2 saturation.
Data was taken at five time points for the TG and NTG. The TG data was taken 
at the last measure before surgery, the first measure after surgery, the last measure 
before transfusion, the first measure after transfusion, and the last measure before 
discharge. The NTG used the last measure before surgery, the first measure after 
surgery, two points during the recovery period, and the last measure before discharge. 
The two values from the NTG recovery period were generated by averaging the results 
from the first and second halves of the patient’s post-surgical stay. Patients without data 
at all five time points were removed from the analysis.
Statistical Analysis
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A repeated measures analysis of variance (rANOVA) was used to look at 
changes in metabolites/blood characteristics over time. The rANOVA reports on the 
significance of trends within and between subjects. The within subject analysis was 
utilized to determine if the values changed significantly over time. More importantly, the 
within subject analysis were used to identify if transfusion had a significant effect on the 
values over time. The Mauchly's Test of Sphericity was implemented to determine 
sphericity, a statistical test to see if there is equal variance in the differences between the 
data points within a group (Lund 2013). The Greenhouse-Geisser correction, considered 
to be a conservative correction, was applied to situations where sphericity could not be 
assumed (Lund 2013). The between subjects portion of the rANOVA made it possible 
to examine if there was a significant difference in the values of NTG and TG overall and 
at a given time point.
Analyses were performed using the SPSS statistical software package version 
19.0 (IBM/SPSS Inc., Chicago, IL). All statistical tests were performed by an 
experienced statistician (Dr. Richard Shaw, PhD, The Valley Columbia Heart Center). A 
value of p <  0.05 was used to determine the statistical significance of all tests used.
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CHAPTER 3
RESULTS
Descriptive Statistics
Patients receiving blood products were found to be older, more likely to be 
female, with higher rates of diabetes, MI history, renal failure, NYHA Class III-IV heart 
failure, more severe coronary disease and more urgent presentation. A comprehensive 
breakdown of the overall patient population can be found in Table 2 (page 31). The 
baseline characteristics of the two groups did not differ significantly as demonstrated by 
a univariate analyses (Table 3). Using the Society of Thoracic Surgeons (STS) Risk 
Adjusted Scores (Shahian, O'Brien et al. 2009; Jin, Fumary et al. 2010), the two groups 
were predicted to have similar outcomes; this further supports the homogeneity of the 
two groups (Table 4).
Table 3: Propensity-Matched Patient Characteristics and Predicted Outcomes
Group Non-Transfused Transfused
n= 318 318
Male 228 71.7% 240 75.5%
Age 68.45 ± 11.0 66.69 ±6.3
Body Surface 
Area
1.98 ±0.2 1.96 ±0.2
Body Mass Index 28.25 ± 4 . r 28.68 ±5.8
Urgent Surgery 209 65.7% 202 63.5%
Smoker 176 55.3% 191 60.1%
Myocardial
Infarction
158 49.7% 167 52.5%
Angina 147 46.2% 171 53.8%
New York Heart 
Association 
Class III-IV
68 21.4% 77 24.2%
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Diabetes 117 36.8% 113 35.5%
Ejection Fraction 52.06 ± 11.1 52.88 ±13.8
Renal Failure 20 6.3% 16 5.0%
Dialysis 2 0.6% 4 1.3%
Cardiogenic
Shock
4 1.3% 1 0.3%
Table 4: Calculated Society of Thoracic Surgeons Predicted Outcomes
Group Non-Transfused Transfused
Predicted Morbidity and Mortality 13.0% ±12.5% 12.0% ±9.5%
Predicted Mortality 1.8% ±8.4% 1.6% ±3.4%
Predicted Renal Failure 3.5% ±9.0% 3.1% ±3.9%
Predicted Re-Operation 4.9% ±3.7% 4.8% ±3.1%
Predicted Stroke 1.4% ±3.3% " 1.5% ± 1.2%
Predicted Prolonged Ventilation 7.3% ± 12.1% 5.8% ±9.1%
Predicted Deep Sternal Wound Infection 0.4% ±0.5% 0.5% ±0.6%
Predicted Length of Stay > 6 Days 50.3% ± 10.0% 53.1% ± 10.1%
Predicted Length of Stay >14 Days 4.9% ±9.6% 4.3% ±4.9%
During data collection, it was discovered that 13 patients in the TG had transfusions 
before their CABG and were subsequently removed from the study. The descriptive 
statistics for each measure will be discussed below.
Within Subjects
All of the measures were found to have p=0.000 for Mauchly's Test of 
Sphericity, indicating none of the data could be considered to meet the condition of 
assumed sphericity for the within subjects categories of Time and Time*Group. 
Therefore, the Greenhouse-Geisser correction is reported for these categories (Table 5, 
next page).
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Table 5: Within Subject Effects of Time and Transfusion on Blood Characteristics.
Df III ; ;TimeP-
value
Prime *
T ransfu sion
Time *
Transfusion
p-value
Ca2+ 2.86 1431.88 687.50 0.000 26.49 0.000
GLU 2.26 1147.39 15.11 0.000 0.50 0.629
BUN 2.61 1325.24 55.42 0.000 3.28 0.026
CR 2.98 1514.47 49.11 0.000 3.28 0.020
Na+ 1.01 513.49 2.02 0.156 0.72 0.399
K+ 1.01 512.86 3.03 0.082 1.49 0.223
cr 2.32 1175.85 93.30 0.000 2.56 0.069
c o 2 3.31 1680.11 335.78 0.000 22.76 0.000
PT 1.18 497.43 26.54 0.000 0.18 0.714
INR 1.81 760.02 42.85 0.000 2.31 0.105
aPTT 1.96 735.11 1.23 0.294 1.11 0.330
pH 1.62 684.96 6.93 0.002 3.67 0.035
Pc o 2 1.67 708.34 10.85 0.000 3.17 0.052
p 02 1.87 791.39 292.68 0.000 37.73 0.000-,............. .......,........... ..-..-.... .....1
h c o 3 1.10 467.16 3.11 0.075 3.04 0.078
0 2 Sat 1.25 529.32 1.69 0.194 0.18 0.732
_ j
WBC 2.34 1224.26 270.34 0.000 8.85 0.000
RBC 2.15 1123.87 192.99 0.000 8.75 0.000
HGB 1.01 562.66 8.05 0.005 2.02 0.155
HCT 1.39 780.46 150.76 0.000 11.52 0.000
MCV 1.05 546.61 1.23 0.271 0.90 0.348
MCH 2.71 1414.84 16.80 0.000 3.15 0.029
MCHC 3.43 1791.54 12.11 0.000 5.87 0.000
RDW 1.04 541.40 11.59 0.001 0.89 0.356
PLT 2.24 1164.69 226.97 0.000 23.48 0.000
MPV 1.85 963.83 4.03 0.021 1.32 0.267
Time refers to the test to determine if the measure changes over time. The Time 
* Group test determines if transfusion significantly affects this change over time. The 
results in Table 5 indicate that 21 blood characteristics (Ca , GLU, BUN, Cr, Cf. CO2, 
PT, INR, pH, pC 02, p 0 2, 0 2 saturation, WBC, RBC, HGB, HCT, MCH, MCHC, RDW, 
PLT, and MPV,) change significantly over time. However, when the effect of
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transfusion on these changes over time was tested, there were fewer significant changes 
with only 12 factors being significant: Caz+, BUN, Cr, CO2, pH, p 0 2, WBC, RBC, 
MCH, MCHC, PLT, and HCT. There were no significant differences seen in Na+, K+. 
aPTT, HCO3', and MCV in either within subject test.
Between Subjects
The between subject test identifies if the values of a given measure for NTG and 
TG are significantly different. Overall, 11 categories were different between the NTG 
and TG: Ca2+, BUN, CR, CO2, ALP, INR, pH, p02, HCO3', O2 saturation, RBC, and 
HCT (Table 6).
Table 6: Between Subjects Test to Determine if Transfusion Effects Overall 
Measurement Values
Category Df dferror F p- Category df dferror F p-
________________________ value___________________________ value
Ca2+ 1 508 21.877 0.000 pco2 1 424 0.461 0.497
GLU 1 508 0.209 0.648 p02 1 424 46.313 0.000
BUN 1 508 4.775 0.029 h c o 3 1 424 27.397 0.000
CR 1 508 3.981 0.047 0 2 Sat 1 424 8.068 0.019
Na+ 1 508 0.743 0.389 WBC 1 523 2.078 0.150
K+ 1 508 1.437 0.231 RBC 1 523 41.424 0.000
cr 1 508 1.084 0.298 HGB 1 560 0.001 0.980
co 2 1 508 19.600 0.000 HCT 1 560 60.885 0.000
PT 1 422 1.408 0.236 MCV 1 523 1.061 0.303
INR 1 421 28.631 0.000 MCH 1 523 0.018 0.894
aPTT 1 375 2.078 0.150 MCHC 1 523 2.634 0.105
TBIL 1 159 0.559 0.456 RDW 1 523 0.854 0.356
pH 1 424 32.035 0.000 PLT 1 523 2.962 0.086
ALT 1 159 0.587 0.445 MPV 1 523 0.785 0.376
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A sub-analysis of the between groups analysis was performed to examine if there 
is difference between the NTG and TG values at each time point. The results of the 
Chemistry tests are displayed in Table 7, A graphical representation of these results can 
be found in Supplemental Figure 1 (page 55). Significant differences were found at 
certain time points for Ca2+ (at time points 3 & 4), BUN (1, 3, & 5), CR (1), C f (4), and 
CO2 (4). There were no significant differences in GLU, Na+, and Kf concentrations 
between the two groups.
Table 7: Mean Chemistry Values over Time
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p-value 0.062 0.280 0.923 0.000 0.057
Table 8 represents the results of the Coagulation tests between measures analysis. All 
three measures had significant differences: PT (time point 1), INR (2-5), and aPTT (5). 
Supplemental Figure 2 (page 57) displays traces of how these three measurements change 
over time.
Table 8: Mean Coagulation Times
The results of the Cardiac/Critical Care group can be found in Table 9 (Supplemental 
Figure 3, page 58). There were significant differences at each time point for both pH and 
HCCb'. Significant differences were seen in pC>2 at time points 1 -3 and O2 saturation at 
time point 3. There were no significant differences for pCC>2.
Table 9: Mean Results of the Cardiac/Critical Care Measurements
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pC02 NTG 318 37.58 38.04 38.50 38.34
TG 108 36.82 37.14 39.37 37.87
p-value 0.234 0.146 0.147 0.406
p02 NTG 318 211.20 191.07 130.49 125.72
TG 108 322.81 243.43 175.65 126.18
p-value 0.000 0.000 0.000 0.960
CSHC03 NTG 318 22.17 22.15 22.65 22.81
TG 108 23.27 25.81 24.08 29.44
p-value 0.000 0.005 0.000 0.000
02 Sat NTG 318 98.06 97.86 97.70 97.55
TG 108 99.35 99.14 98.86 98.41___
p-value 0.065 0.075 0.000 0.095
The Hematology results are displayed in Table 10 (Supplemental Figure 4, page 59). 
Values were significantly different for HCT at all points. Significance was also achieved 
at difference time points for WBC (at time point 3), RBC (1, 3, 4, & 5), HBG (2-5), 
MCHC (3 & 4), and PLT (2-5). MCV, MCH, and MPV showed no significant 
differences.
Table 10: Mean Hematology Values Over Time
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MCV NTG 317 90.11 90.13 91.31 90.84 90.49
TG 208 89.95 89.94 90.07 89.79 90.24
p-value 0.729 0.685 0.303 0.092 0.563
MCH NTG 317 30.77 30.85 30.88 30.93 30.88
TG 208 30.71 30.86 30.94 30.88 30.80
p-value 0.747 0.953 0.733 0.775 0.639................
MCHC NTG 317 34.12 34.21 34.17 34.14 34.11
TG 208 3.13 34.29 34.33 34.38 34.11
p-value 0.964 0.215 0.050 0.000 0.996
RDW NTG 317 13.91 13.83 14.07 14.26 14.38
TG 208 13.62 13.57 13.77 14.32 14.34
p-value 0.039 0.068 0.031 0.793 0.927
PLT NTG 317 224.74 184.31 176.03 204.98 238.59
TG 208 220.52 172.25 162.32 166.75 261.25
p-value 0.553 0.028 0.008 0.000 0.010
MPV NTG 317 8.24 8.14 8.27 8.66 8.36 i
TG 208 8.18 8.10 8.27 8.29 8.39
p-value 0.524 0.588 0.950 0.087 0.909
CHAPTER 4
DISCUSSION AND CONCLUSIONS
Effect o f Transfusion on Anemia and Oxygen Transport
The primary goal of a blood transfusion is to provide the patient’s tissues with 
more oxygen through replacement of lost or impaired RBC. For the most part, 
transfusion does have an effect on how measures of anemia and oxygen transport trend 
over time. In total, ten of the sixteen measures used to monitor anemia and oxygen 
transport were found to be significantly affected by the administration of blood products.
Patients developed anemia after surgery. As demonstrated by Figures 5-9, RBC, 
HGB, and HCT for of the average NTG and TG patient fell below normal values. It is 
interesting to find that the TG has lower RBC, HGB, and HCT than NTG throughout 
their post-operative stay, which could be the driving factor for why those patients 
received transfusions. However, even with after their transfusion, these patients fail to 
reach non-significant differences with their NTG counterparts. Furthermore, the changes 
in HGB were significant over time, but were not found to be affected by transfusion.
This suggests that HGB levels did not respond to transfusion. This is important as most 
guidelines use low HGB as an indicator for the need of blood transfusion (Ferraris, 
Ferraris et al. 2007). Regarding these guidelines, it is interesting to note that the average 
TG patient received a transfusion at a HGB of ~9g/dL, suggesting that most of these 
patients could did not meet the basic requirement for a transfusion. However, there
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could have been other factors that guided the physician’s decision to transfuse these 
patients beyond HGB,
There does not appear to be a standard type of post-surgical anemia, as the 
average MCV, MCH, and MCHC stay within their normal ranges. The MCV, based 
upon the ratio of HCT to RBC, demonstrated no significant changes or differences, 
which was not surprising given how similarly the two measures tracked. On the other 
hand, MCH and MCHC (ratios dependent on the HGB), were found to be significantly 
affected by transfusion. This may be an artifact due to the fact the changes in HGB were 
not influenced by transfusion while RBC and HCT (the denominator of MCH and 
MCHC, respectively) were. Lastly, the fourth method available to identify the type of 
anemia, RDW, demonstrated no effects from transfusion. Notably, the NTG RDW is 
initially much higher (significant at T=1 and T=3), but transfusion brings the RDW of 
the TG up to the level of the NTG’s RDW. This is not necessarily a benefit, as a higher 
RDW is an indicator of anemia.
It would be a reach to claim that transfusions do not effectively treat anemia. It is 
possible that that transfusion either helps to jump-start the body’s natural response to 
anemia or simply stabilizes the patient long enough for the recovery process to begin on 
its own, as RBC, HGB, and HCT values continue to rise after transfusion.
The main concern for patients with anemia is the potential for decreased tissue 
oxygenation. This study looks at several factors that affect or describe the blood’s 
oxygen-carrying capacity. It is hard to state with any certainty the true effects of 
transfusion on the Cardiac/Critical Care variables as most TG patients started with
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significantly higher values. However, it is possible to compare the trends between the 
two groups. Looking at oxygen directly, the results show that pC>2 and O2 saturation 
were higher in the TG than NTG immediately after transfusion. Transfusion was shown 
to be associated with the TG’s p02 decline to that of the NTG’s; however, this was not 
the case with O2 saturation.
As stated previously, pH and CO2 also affect pC>2 carrying-capacity. The blood 
pH of the TG was significantly higher than that of the NTG, but not so much that is was 
outside of the normal range. Paradoxically, CO2 concentration in TG was lower than the 
NTG immediately after transfusion, but pC02 was higher (albeit not to a significant 
extent). Likewise, CO2 levels were significantly affected by transfusion, but not pC02. 
This could be a manifestation of the Haldane effect due to the increase in 02-saturated 
HGB after transfusion. Even more striking is the fact that while HCO3’ was significantly 
higher in the TG, it was not affected by transfusion itself (or time, for that matter). This 
may be the result of decreasing concentrations of H^ and CO2, which would maintain the 
equilibrium of the HCOs'reaction (found on page 29). It would also explain the increase 
in O2 saturation, as a decrease in both of these concentrations would create a left shift in 
the oxygen dissociation curve.
Effect o f Transfusion on Coagulation
Overall, transfusion does not seem to affect coagulation in any significant way. 
The administration of blood products was only associated with increasing PLT, inducing 
a steep increase at T=4. Otherwise, the other measures of coaguability (PT, INR, aPTT, 
and MPV) were shown to change independently of transfusion. This may be explained
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by the common practice of administering anti-coagulant medications to patients after 
cardiac surgery to reduce the risk of clotting. While both groups should have received 
the same treatment in this regard, it is possible that the drugs masked the effects of 
transfusion.
Effect o f Transfusion on Liver Function
It is difficult to determine if transfusion has an effect on liver function. However, 
it has already been established that three of the “liver function” measures (PT, INR, 
aPTT) were likely affected by anti-coagulation medications. The last liver function 
measurement that was found to be associated with transfusion was glucose. However, 
this too may be the result of normal hospital practice. As previously stated, patients 
become hyperglycemic after surgery (McCowen, Malhotra et al. 2001); this is evident in 
the glucose traces in Figure 6. However, glucose levels rapidly fall in both groups. This 
is likely due to the fact that glucose levels are tightly controlled in the hospital as a 
means to prevent infection (Lazar, Chipkin et al. 2004; Leibowitz, Raizman et al. 2010; 
Bhamidipati, LaPar et al. 2011; Haga, McClymont et al. 2011; Stamou, Nussbaum et al. 
2011). Given that all four hepatic function measurements are tightly controlled by 
physicians in the hospital, it is nearly impossible to draw any definitive conclusions on 
the possible effects of transfusion on the liver.
Effect o f Transfusion on Renal Function and Osmoregulation
As the organ responsible for filtering metabolic waste from the blood, it stands to 
reason that the introduction of new blood would have an effect on kidney function. The
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9 -4-results shown here may support this idea, as Ca , BUN, and CR (three of the five 
markers of renal function) were shown to be significantly affected by transfusion. The 
TG patients were shown to be hypocalcaemic and have higher levels of BUN and CR 
overall, all are indicative of renal insufficiency. However, Ca levels are affected by 
many things, not just the kidneys. In addition, BUN and CR (the measures most 
reflective of renal function) were not significantly higher after transfusion, so it is 
possible that additional factors may be at play here other than transfusion. Looking at 
the secondary function of the kidney, osmoregulation, the results indicate that the other 
ions measured in this study (Na+, K+, and Cf) were all unaffected by transfusion.
Limitations
There are several limitations to this study. The most apparent is the fact that this is 
a retrospective observational study and because of this, the patient population is not 
randomized and there is no true control. The time and amount of measurements were not 
standardized among the patient population. In addition, patients were being treated 
according to their personal needs and not a protocol; therefore, patients likely had 
different experiences and treatments during their stay.
However, steps were taken to address these issues. The propensity-matching was 
utilized to create balanced groups with similar background demographics, thus creating 
a pseudo-randomization. When groups are propensity matched, the researcher can 
confidently use standard statistical models to estimate casual relationships within the 
dataset (Rubin 1997). Furthermore, given that data for 26 variables were collected for 
every blood test that the 636 patients underwent during their hospital stay, thousands of
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data points were analyzed in this project. Furthermore, the patient population was 
selected to be free of post-operative mortality and complications, in order to limit the 
effects of secondary treatments. These methods lend tremendous power and credibility 
to the results.
Conclusions
This study aimed to examine the effects of transfusion on blood composition and 
characteristics using a propensity-matched cohort of 636 patients that underwent CABG 
with no complications. The investigation did not provide evidence that transfusion cured 
anemia, the most commonly cited concern linked to the need for blood products. 
However, it did support the claim that transfusion provides a boost in oxygen-carrying 
capacity. This boost may come at the cost of renal function.
As a retrospective study, these results do not prove that transfusion causes 
anything. Causation can only be determined by a prospectively randomized and 
controlled study. Rather, this study identifies certain aspects that physicians may want to 
consider when deciding to give a patient blood.
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